Technology
Health
Pharmaceutical

Aileron Therapeutics

$0.525
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0165 (-3.05%) As of 12:00 PM EDT today
-$0.0165 (-3.05%) Today

Why Robinhood?

You can buy or sell ALRN and other stocks, options, ETFs, and crypto commission-free!

About ALRN

Aileron Therapeutics, Inc. Common Stock, also called Aileron Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. Read More It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

Employees
23
Headquarters
Watertown, Massachusetts
Founded
2005
Market Cap
8.05M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
483.86K
High Today
$0.5574
Low Today
$0.445
Open Price
$0.5477
Volume
470.78K
52 Week High
$4.49
52 Week Low
$0.445

Collections

Technology
Health
Pharmaceutical
2017 IPO
US
North America

ALRN News

MarketWatchJul 5

Aileron Therapeutics Inc.

233

ALRN Earnings

-$0.56
-$0.47
-$0.37
-$0.28
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours

More ALRN News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.